MBX Biosciences MBX 深 沪
等待开盘 08-25 09:30:00 美东时间
66.39
+0.060
+0.09%
华盛通- 最 高67.155
- 今 开66.23
- 成交量 53.11万股
- 最 低 64.00
- 昨 收 66.33
- 总市值 31.97亿
- 52周最高 72.64
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 9.63
- 委 比 55.33%
- 总股本 4816.01万
- 历史最高 72.64
- 量 比 1.07
- 振 幅 4.76%
- 历史最低 4.8069
- 每 手 1
- 风险率 15.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 罗斯百货、迪尔股份获多家大行上调目标价；沃尔玛、Advance遭多家大行下调目标价
今日重点评级关注：摩根士丹利：维持Ultragenyx Pharmaceutical"超配"评级，目标价从67美元升至74美元；Truist Securities：维持Solid Biosciences"买入"评级，目标价从16美元升至20美元
08-24 16:40
JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target
JP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and announces $88 price target.
08-22 03:01
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88
Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $88.
08-11 02:11
MBX Biosciences GAAP EPS of -$0.78
MBX Biosciences press release (MBX): Q2 GAAP EPS of -$0.78. Cash and Cash Equivalents and Marketable Securities: As of June 30, 2026, MBX had cash, cash equivalents and marketable securities of $418.6...
08-06 20:19
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences reported Q2 2026 financial results with $418.6 million in cash and investments, supporting operations into 2029. Key highlights include: Phase 2 and one-year OLE data for weekly canvuparatide showing sustained benefit for chronic hypoparathyroidism, with Phase 3 trial recruitment ongoing. Initial Phase 1 data for monthly dosing MBX 4291 in obesity showed 7% weight loss. MBX 6180, a triple GLP-1/GIP/GCG agonist, was nominated as a ...
08-06 12:00
美股大行评级 | 最高1400美元！花旗、大小摩8家大行上调希捷科技目标价；大行集中调整目标价：康宁、科斯塔、思佳讯遭下调，PayPal、Visa、可口可乐、赛莱默获上调
今日重点评级关注：古根海姆：维持ProMIS Neurosciences"买入"评级，目标价从35美元升至69美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从38美元升至39美元
07-30 11:45
Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91
Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $57 to $91.
07-29 23:50
MBX Biosciences Appoints Steve Hoerter As Chairman And CEO, Succeeding Kent Hawryluk, With John Smither Named Interim CFO, Effective Immediately
MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its Board of Directors has appointed Steve Hoer...
07-14 04:19
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
MBX Biosciences announces leadership changes: Steve Hoerter appointed as CEO, replacing Kent Hawryluk, and John Smither as CFO. Hoerter, a biotech veteran, succeeds Hawryluk, who co-founded the company and led its growth. The company remains focused on advancing precision peptide therapies for endocrine and metabolic disorders, with key milestones expected in 2026.
07-13 20:15
